Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy Compared to VYNDAQEL 20 mg Pharmaceutical Investing
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update Medical Device Investing
Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through One By One Recycling Program Medical Device Investing
Bristol Myers Squibb to Participate in Wolfe Research's 2nd Annual Virtual Healthcare Conference Biotech Investing
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Pharmaceutical Investing
Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020 Biotech Investing
Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens Pharmaceutical Investing
